Here are some of the largest recent moves: (icosapent ethyl) (IPE) reduced composite cardiovascular (CV) endpoint events regardless of baseline levels of low-density lipoprotein cholesterol (LDL-C ...

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide. Cardiovascular (CV) risk reduction is important in patients at high risk for a first ...

vascepa/vazkepa – icosapent ethyl or IPE – reduced composite cardiovascular endpoint events regardless of baseline levels of low-density lipoprotein cholesterol. IPE, which is the active ...

Forward-Looking Statements This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, ...